| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2004 | US6761898 Carnitine or alkanoyl-l-carnitine and glucosaminoglycan |
| 07/13/2004 | US6761895 Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| 07/13/2004 | US6761879 Titanium derived compounds, preparation and use thereof |
| 07/13/2004 | CA2453282A1 Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal |
| 07/13/2004 | CA2386775C Drugs for the treatment of malignant tumours |
| 07/13/2004 | CA2375537C Topically applied idebenone-containing agent with protective and regenerative effect |
| 07/13/2004 | CA2348882C Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol |
| 07/13/2004 | CA2313106C Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents |
| 07/13/2004 | CA2311356C Method for treating alzheimer's disease |
| 07/13/2004 | CA2301267C Method of enhancing bioavailability of fexofenadine and its derivatives |
| 07/13/2004 | CA2286684C Controlled release formulations using intelligent polymers |
| 07/13/2004 | CA2268684C Process for alkylating hindered sulfonamides |
| 07/13/2004 | CA2260143C Anthelmintic formulations |
| 07/13/2004 | CA2259270C Pharmaceutical preparation containing nimesulide for oral administration |
| 07/13/2004 | CA2255652C Isobutylgaba and its derivatives for the treatment of pain |
| 07/13/2004 | CA2238040C Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications |
| 07/13/2004 | CA2193363C Therapeutic agent for liver regeneration |
| 07/13/2004 | CA2192255C Treatment of chlamydia infectious diseases by rifamycin derivative |
| 07/13/2004 | CA2158354C Use of granisetron for the treatment of post-operative nausea and vomiting |
| 07/13/2004 | CA2155020C Antiviral naphthoquinone compounds, compositions and uses thereof |
| 07/13/2004 | CA2137748C Amidinophenylalanine derivatives, a process for their preparation, their use and compositions containing these as anticoagulants |
| 07/13/2004 | CA2118859C Enantiomers of 1-[(4-chlorophenyl)-phenylmethyl]-4-[(4-methylphenyl)sulfonyl]piperazine |
| 07/13/2004 | CA2067062C Infusion preparation |
| 07/13/2004 | CA2064117C 4"-and 4'-alkylthio-avermectin derivatives |
| 07/13/2004 | CA2047699C Expanded porphyrins: large prophyrin-like tripyrroledimethine-derived macrocycles |
| 07/08/2004 | WO2004056998A1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 07/08/2004 | WO2004056992A1 Three-dimensional structure of lipocalin-type prostaglandin d synthase and utilization of the same |
| 07/08/2004 | WO2004056971A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 07/08/2004 | WO2004056869A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 07/08/2004 | WO2004056844A1 Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4”- or 4’-position |
| 07/08/2004 | WO2004056843A2 10-substituted macrolide antibiotics |
| 07/08/2004 | WO2004056830A1 Pyrrolopyrimidine derivatives |
| 07/08/2004 | WO2004056823A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS |
| 07/08/2004 | WO2004056821A2 Quinolizidine derivatives |
| 07/08/2004 | WO2004056820A1 Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| 07/08/2004 | WO2004056819A1 Oxazolidinone derivatives as antibacterial agents |
| 07/08/2004 | WO2004056814A1 Oxazoles as mglur1 enhancer |
| 07/08/2004 | WO2004056811A1 Flavaxate derivatives as muscarinic receptor antagonists |
| 07/08/2004 | WO2004056810A1 Xanthine derivatives as muscarinic receptor antagonists |
| 07/08/2004 | WO2004056806A1 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases |
| 07/08/2004 | WO2004056802A1 Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
| 07/08/2004 | WO2004056800A1 Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 07/08/2004 | WO2004056799A2 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 07/08/2004 | WO2004056791A1 Escitalopram hydrobromide and a method for the preparation thereof |
| 07/08/2004 | WO2004056787A1 Cyclopentyl glutaramides and their use as neutral endopeptidase inhibitors |
| 07/08/2004 | WO2004056784A1 Novel carboxamides, the production and use thereof as medicaments |
| 07/08/2004 | WO2004056782A1 Pyrazole compounds |
| 07/08/2004 | WO2004056780A2 Tetrahydroquinoline derivatives |
| 07/08/2004 | WO2004056773A1 Novel piperidine derivatives as modulators of chemokine receptor ccr5 |
| 07/08/2004 | WO2004056768A2 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
| 07/08/2004 | WO2004056764A1 Aromatic derivatives as hiv aspartyl protease inhibitors |
| 07/08/2004 | WO2004056763A2 Novel glucagon antagonists |
| 07/08/2004 | WO2004056762A2 Novel aminobenzophenone compounds |
| 07/08/2004 | WO2004056751A1 Antibacterial agents |
| 07/08/2004 | WO2004056750A1 Cyclopentil-substituted glutaramide compounds as endopeptidase inhibitors |
| 07/08/2004 | WO2004056748A1 Therapeutic agents |
| 07/08/2004 | WO2004056745A2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 07/08/2004 | WO2004056744A1 Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| 07/08/2004 | WO2004056740A1 Dicarboxylic acid derivatives as ppar-agonists |
| 07/08/2004 | WO2004056396A1 DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE |
| 07/08/2004 | WO2004056395A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 07/08/2004 | WO2004056394A1 Combinations of a vanilloid antagonist and an nsaid for the treatment of pain |
| 07/08/2004 | WO2004056380A2 Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
| 07/08/2004 | WO2004056379A1 Saponins and sapogenins for use in combination therapy for cancer |
| 07/08/2004 | WO2004056376A1 Pharmaceutical formulations containing nitrate |
| 07/08/2004 | WO2004056374A1 Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patients |
| 07/08/2004 | WO2004056373A1 High dose ibandronate formulation |
| 07/08/2004 | WO2004056372A1 Use of aglycon protopanaxadiol in cancer therapy |
| 07/08/2004 | WO2004056371A1 Use of aglycon protopanaxatriol in cancer therapy |
| 07/08/2004 | WO2004056370A1 Use of a fatty acid composition for treatment of male infertility |
| 07/08/2004 | WO2004056368A1 Therapeutic applications of 2-substituted 4-heteroarylryrimidines |
| 07/08/2004 | WO2004056367A1 Treatment of von hippel lindau disease |
| 07/08/2004 | WO2004056363A2 A physically and chemically stable nicotine-containing particulate material |
| 07/08/2004 | WO2004056362A2 8-trialkysyloxy-2-methyl-9-phenyl-7-0 xo-7,8,9,10- tetrahydroimidazo ‘1,2-h! ‘1,7! naphthyridines |
| 07/08/2004 | WO2004056361A1 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents |
| 07/08/2004 | WO2004056360A1 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination |
| 07/08/2004 | WO2004056359A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | WO2004056358A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | WO2004056357A1 Composition comprising diclofenac for treating otic pain and inflammation |
| 07/08/2004 | WO2004056356A1 Oil-acid emulsion and use thereof |
| 07/08/2004 | WO2004056355A1 USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY |
| 07/08/2004 | WO2004056354A1 Controlled release pharmaceutical compositions of tamsulosin |
| 07/08/2004 | WO2004056353A2 Device and method for delivering mmp inhibitors |
| 07/08/2004 | WO2004056352A1 TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS |
| 07/08/2004 | WO2004056351A1 Pka activity regulator |
| 07/08/2004 | WO2004056350A1 Use of hypericin and/or the derivatives thereof for the prevention of primary tumours |
| 07/08/2004 | WO2004056349A2 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 07/08/2004 | WO2004056348A2 Natural vitamin e compositions with superior antioxidant potency |
| 07/08/2004 | WO2004056347A2 Pharmaceutical compositions comprising insulin and legends of insulin hexamer |
| 07/08/2004 | WO2004056344A1 Slow release formulation of clarithromycin |
| 07/08/2004 | WO2004056342A1 Process for preparing combination pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | WO2004056341A1 Process for preparing pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | WO2004056337A2 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| 07/08/2004 | WO2004056336A2 Controlled release, multiple unit drug delivery systems |
| 07/08/2004 | WO2004056324A2 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| 07/08/2004 | WO2004056323A2 Method of treating angiogenic tissue growth |
| 07/08/2004 | WO2004056322A2 Antibiotics containing borinic acid complexes and methods of use |
| 07/08/2004 | WO2004056320A2 Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
| 07/08/2004 | WO2004056317A2 Compositions for the treatment and prevention of nephropathy |
| 07/08/2004 | WO2004056315A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |